Imaging disease mechanisms in people with als

ALS drug development faces many challenges that result in very high failure rates of tested therapies. Unfortunately, most ALS therapies that show encouraging results in the lab do not translate into effective treatments for people with ALS. One of the biggest challenges in ALS drug development is the lack of a mechanistic readout of drug efficacy in patients at early phases of clinical drug development. Our team at Mass General Hospital (MGH) is laser-focused on building these needed imaging mechanistic platforms.